| scholarly article | Q13442814 |
| P2093 | author name string | Abdurrahman Kara | |
| Ali Fettah | |||
| Neşe Yaralı | |||
| Tekin Aksu | |||
| Vildan Koşan Çulha | |||
| İkbal Ok Bozkaya | |||
| Namık Yaşar Özbek | |||
| Mehmet Baştemur | |||
| P2860 | cites work | Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups | Q28143548 |
| Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia | Q28291815 | ||
| The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia | Q28320997 | ||
| A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements. | Q34002945 | ||
| Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia | Q34108096 | ||
| Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group | Q34692984 | ||
| A Multicenter Experience from Lebanon in Childhood and Adolescent Acute Myeloid Leukemia: High rate of Early Death in Childhood Acute Promyelocytic Leukemia | Q34822047 | ||
| Global characteristics of childhood acute promyelocytic leukemia | Q35231673 | ||
| Acute promyelocytic leukemia: recent advances in diagnosis and management | Q37240576 | ||
| Pseudotumor Cerebri in Acute Promyelocytic Leukemia Patients on Intergroup Protocol 0129: Clinical Description and Recommendations for New Diagnostic Criteria | Q37267511 | ||
| How I treat children and adolescents with acute promyelocytic leukaemia | Q37451376 | ||
| Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia | Q37919763 | ||
| Acute promyelocytic leukemia in children and adolescents | Q38250290 | ||
| Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy | Q38735007 | ||
| Current management of newly diagnosed acute promyelocytic leukemia | Q38809825 | ||
| Molecular Characteristics and Clinical Significance of 12 Fusion Genes in Acute Promyelocytic Leukemia: A Systematic Review | Q38810996 | ||
| Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. | Q39023642 | ||
| Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses | Q39924178 | ||
| High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group. | Q40735293 | ||
| Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias | Q42220357 | ||
| Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. | Q44586697 | ||
| Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. | Q44844886 | ||
| GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children | Q45242157 | ||
| Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. | Q46025921 | ||
| Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. | Q46165728 | ||
| Acute promyelocytic leukemia: four distinct patterns by flow cytometry immunophenotyping. | Q47850101 | ||
| The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes. | Q51815688 | ||
| Incidence and prognostic importance of molecular genetic defects in children with acute myeloblastic leukemia. | Q54394501 | ||
| All-transretinoic Acid (ATRA) Treatment-related Pancarditis and Severe Pulmonary Edema in a Child With Acute Promyelocytic Leukemia | Q60739720 | ||
| Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity | Q81623816 | ||
| Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia | Q82317096 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | acute promyelocytic leukemia | Q612108 |
| P304 | page(s) | e2018045 | |
| P577 | publication date | 2018-07-01 | |
| P1433 | published in | Mediterranean journal of hematology and infectious diseases | Q27723406 |
| P1476 | title | Acute Promyelocytic Leukemia in Children: A Single Centre Experience from Turkey | |
| P478 | volume | 10 |
Search more.